Compare Adaptive Biotechnologies Corp (ADPT) vs Jumia Technologies AG - ADR (JMIA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Jumia Technologies AG - ADR — how do they compare? Adaptive Biotechnologies Corp trades at $19.85 (market cap $3.33B), while Jumia Technologies AG - ADR trades at $6.74 (market cap $859.54M). The key difference: Adaptive Biotechnologies Corp is far larger — about 3.9× Jumia Technologies AG - ADR's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Jumia Technologies AG - ADR nearer its low. Which is the better fit depends on your goals.
| ADPT | JMIA | |
|---|---|---|
Market Cap | $3.33B | $859.54M |
Sector | Health | Consumer Cyclical |
52-Week High | $22.37 | $14.60 |
52-Week Low | $10.24 | $4.24 |
Enterprise Value | $3.19B | $806.64M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
JMIA trades at $6.94, down 1.56% today, with a bullish technical signal from moving averages. The company reported Q1 2026 revenue growth of 39% year-over-year, narrowing its adjusted EBITDA loss by 32%. Analyst consensus is strongly bullish with 71% buy ratings, supported by management's reaffirmed path to profitability by 2027. Cash flow improved in 2025 with a net inflow of $21.31 million, though the company remains unprofitable with a net income margin of -30.79%.
The outlook hinges on JMIA's execution toward its 2027 profitability target, with upside from African e-commerce expansion and partnerships like Starlink. Key risks include persistent losses, competitive pressures, and macroeconomic volatility in operating regions. Investors should weigh the growth potential against the high valuation multiples and financial sustainability concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Jumia Technologies AG - ADR
Jumia Technologies AG is the pan-African e-commerce platform. The company's platform consists of a marketplace, which connects sellers with consumers. Its logistics service enables the shipment and delivery of packages from sellers to consumers, and the company's payment service facilitates transactions among participants active on its platform in selected markets. Jumia generates revenue from Sales of goods, Commissions, Fulfillment, Value-added services, and Marketing & Advertising. Its geographical segments are West Africa, North Africa, East & South Africa, Europe, and United Arab Emirates. The firm generates most of its revenue from the West Africa segment.
Read more on JMIA →
